Effect of renin-angiotensin system inhibitors in patients with cancer treated with anti-VEGF therapy.
Open heart(2022)
Abstract
RASIs for hypertension do not benefit clinical outcomes during cancer therapy with VSP inhibitors. In addition, RASIs and calcium channel blockers have comparable clinical efficacy as first-line antihypertensive.
MoreTranslated text
Key words
Health Services,Hypertension,Outcome Assessment, Health Care
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined